Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SHPH with free AI briefings, catalyst countdowns, and dilution alerts.

SHPH · Shuttle Pharmaceuticals Holdings, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$90,238 Cash on Hand
0.2mo Cash Runway
Follow SHPH by email Get an email when SHPH reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SHPH, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Ropidoxuridine Glioblastoma, IDH-wildtype Phase 2 · NCT06359379 Terminated

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SHPH holds $90,238 in cash and short-term investments (as of Jun 30, 2026) and burns about $1.5M/quarter from operations, an estimated runway of 0.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 53 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SHPH files for a raise →

👥 Who Owns SHPH

Insiders 38.1% Institutions (6 holders) 2.2% Public and other holders 59.7%
HolderTypeShares% of sharesAs of
Milton Brown
Director
Insider 346,617 7.27% 2024-12-31
Timothy J. Lorber
Chief Financial Officer · +24,854 options
Insider 227,635 4.78% 2024-06-13
Steven M Richards
Director · +29,240 options
Insider 210,004 4.41% 2024-12-31
Joshua Schafer
Director
Insider 210,004 4.41% 2024-12-31
Joseph Tung
Director · +29,240 options
Insider 184,162 3.87% 2025-02-28
Oleh Nabyt
Director · +29,240 options
Insider 184,162 3.87% 2025-02-28
George Scorsis
Director · +29,240 options
Insider 184,162 3.87% 2025-02-28
Mira Jung
Chief Scientific Officer
Insider 135,715 2.85% 2024-05-01
Hoek Michael Vander
Chief Financial Officer
Insider 103,852 2.18% 2024-03-08
Bette Jacobs
Director
Insider 27,064 0.57% 2023-12-13
Chris Senanayake
Director
Insider 2,791 0.06% 2022-12-29

Share count 4,764,696 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SHPH picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SHPH and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.